Urinary bladder cancer (BCa) accounts for about 7% of all new cancers in the United States with 81,190 estimated new cases and 17,240 deaths in 2018. Approximately 75% of the new diagnoses BCa will be non-muscle-invasive BCa (NMIBC) affected by recurrence and progression rates of approximately 60% and 20%, respectively. Several unmet questions have been raised in the urological community regarding BCa. In this series on BCa we collected a series of articles treating some of the most important issue for the urological community.
Editorial
Present and future perspective in the field of bladder cancer
Review Article
Role and efficacy of current biomarkers in bladder cancer
Therapeutic management of Bacillus Calmette–Guerin refractory patients: a narrative review
Enhanced recovery after surgery (ERAS) in patients treated with radical cystectomy
Indication and prognostic value of second transurethral resection in bladder cancer patients
Timing of treatment for muscle-invasive bladder cancer in the neo-adjuvant chemotherapy era
The impact of histological variants on bladder cancer outcomes
Bladder preservation therapy in muscle-invasive bladder cancer: Current evidence and future perspectives
The impact of robotic surgery in bladder cancer patients
The effect of perioperative blood transfusion on oncological outcomes in radical cystectomy patients: a narrative review
The impact of transurethral en bloc resection of bladder tumour on pathological and oncological outcomes
Editorial Commentary
Lymph node dissection during radical cystectomy: indications, extension and impact on survival outcomes
Disclosure:
The series “Bladder Cancer” was commissioned by the editorial office, AME Medical Journal without any sponsorship or funding. Marco Moschini served as the unpaid Guest Editor for the series.